Journal of Oriental Neuropsychiatry (동의신경정신과학회지)

The Korean Society of Oriental Neuropsychiatry (대한한방신경정신과학회)
권호 표지
DOI QR코드

DOI QR Code

Aripiprazole-Related Oculogyric Dystonia

  • Lee, Jae-Eun (Department of Neuropsychiatry, Hospital of Korean Medicine, Kyung Hee University Medical Center) ;
  • Cho, Seung-Hun (Department of Neuropsychiatry, Hospital of Korean Medicine, Kyung Hee University Medical Center)
  • Received : 2013.08.20
  • Accepted : 2013.09.03
  • Published : 2013.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Objectives : Aripiprazole is unique drug among the SGA (Second generation antipsychotics) in its pharmacology and pharmacokinetics,but is similar in clinical efficacy. Aripiprazole acts as a partial agonist at dopamine D2 receptors, activating the receptor but eliciting a reduced response compared to the natural neurotransmitter. There are some side effects of aripiprazole, the most common side effects of aripiprazole are headache, nausea, vomiting, insomnia, tremor, constipation and EPS. Difficulty in opening eyes is not defined EPS yet, but it is a rare but important side-effect symptom of aripiprazole. Methods : This article is about a case of side-effect symptom of aripiprazole, 26-year-old single female suffering from schizophrenia had difficulty in opening eyes while she was taking antipsychotics. During the hospitalization, the relaxation therapy is helpful not only to reduce tension in the eyelids but also to headache. Results : It is important that early recognition of aripiprazole-induced oculogyric dystonia can prevent life-threatening complications. Education medical staff to this easily treatable reaction will improve overall quality of health care. Conclusions : This case notifies the need for awareness of the risk of acute oculogyric dystonia in adolescent female patients receiving aripiprazole.

Keywords

References

  1. Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, et al. Efficacy and Safety of Aripiprazole and Haloperidol Versus Placebo in Patients with Schizophrenia and Schizoaffective Disorder. J Clin Psychiatry. 2002; 63:763. https://doi.org/10.4088/JCP.v63n0903
  2. Bowie CR, Reichenberg A, Patterson TL, Heaton RK, Harvey PD. Determinants of Real-World Functional Performance in Schizophrenia Subjects: Correlations with Cognition, Functional Capacity, and Symptoms. Am J Psychiatry. 2006; 163:418-25. https://doi.org/10.1176/appi.ajp.163.3.418
  3. Lieberman JA, Perkins D, Belger A, Chakos M, Jarskog F, Boteva K, et al. The Early Stages of Schizophrenia: Speculations on Pathogenesis, Pathophysiology, and Therapeutic Approaches [Published Correction Appears in Biol Psychiatry. 2002;51:346]. Biol Psychiatry. 2001;50:884-97. https://doi.org/10.1016/S0006-3223(01)01303-8
  4. Komossa K, Rummel-Kluge C, Schmid F, Hunger H, Schwarz S, El-Sayeh HG. Aripiprazole Versus Other Atypical Antipsychotics for Schizophrenia. Cochrane Database Syst Rev. 2009;CD006569.
  5. Alexopoulos GS, Streim J, Carpenter D, Docherty JP. Using Antipsychotic Agents in Older Patients. J Clin Psychiatry. 2004;65(Suppl 2):5
  6. Goga JK, Seidel L, Walters JK, Khushalani S, Kaplan D. Acute Laryngeal Dystonia. Associated With Aripiprazole. JCP. 2012;32(6):837-9.
  7. Friedman JH. Tardive Dystonia due to Aripiprazole Use in a Neuroleptic-Naive Patient. J Clin Psychiatry. 2010;71:652-3. https://doi.org/10.4088/JCP.09l05836gre
  8. Lim HK, Pae CU, Lee C, Lee CU. Tardive Dystonic Symptoms Associated with Aripiprazole Treatment. J PNPBP. 2008;32:589-90.
  9. Desarkar P, Thakur A, Sinha VK. Aripiprazole-induced Acute Dystonia. AJP. 2006;163(6):1112-3. https://doi.org/10.1176/ajp.2006.163.6.1112
  10. Pena MS, Yaltho TC, Jankovic J. Tardive Dyskinesia Secondary to Aripiprazole. Ann Neurol. 2010; 68:S21-S21.